The dramatic rise in non-Hodgkin's lymphoma (NHL) incidence and mortality throughout the world (1,2) has prompted investigators to search for biomarkers that might indicate an increased predisposition for NHL development. Moreover, although combination chemotherapy has improved the outcome of patients with intermediate-and highgrade NHL (3, 4) , a substantial fraction of these patients still achieve only a partial remission and/or will ultimately relapse. If such patients could be identified at diagnosis by means of new prognostic markers, they might benefit from strategies other than conventional chemotherapy.
The H-RAS 1 proto-oncogene has an associated hypervariable minisatellite that is believed to be capable of influencing H-RAS 1 gene transcription (5, 6) . Rare alleles of this minisatellite, H-RAS 1 VNTR (variable number of tandem repeats), have been associated with a predisposition to acute leukemia (7) and carcinomas of the lung (8) (9) (10) , testis (11) , breast (7, 12) , colorectum (7) , and urinary bladder (7); however, associations with clinical data are not available in any of these studies.
This hypervariable minisatellite, which maps 1 kilobase downstream from the polyadenylation signal of the human H-RAS 1 proto-oncogene, originated through the tandem replication of a 28-base-pair (bp) consensus motif (13) . Population genetic analysis has defined this as a complex locus, in which several dozen rare H-RAS 1 VNTR alleles have arisen from mutation of four common alleles (a1, a2, a3, and a4). The rare alleles seem to differ from the common ones not only in the number of 28-bp repeat motifs that comprise them (14, 15) but also in the interspersion pattern of the five different types of 28-bp repeat motifs described thus far in the VNTR sequence (16) . The distribution of allelic frequencies in matched populations of cancer patients and cancerfree control subjects has indicated that this process of allele mutation may not be merely fortuitous. Rare H-RAS 1 alleles appear, in aggregate, twice as often in the genomes of cancer patients (17) (18) (19) , an observation that now rests on a sample size of approximately 8500 alleles from 23 independent studies (7). This association has suggested the possibility that H-RAS 1 VNTR may interact with cellular elements that control gene expression. In fact, it has already been demonstrated that at least four members of the rel/NF-B family of transcription factors bind this H-RAS 1 minisatellite and that, like other NF-B binding sites, H-RAS 1 VNTR displays promoter-and cell-type-specific transcriptional regulatory activity (5) . It is hypothesized that, by binding rel/NF-B factors (6) , the H-RAS 1 minisatellite is capable of activating and repressing H-RAS 1 gene transcription. Moreover, the fact that variations in the interspersion pattern of the 28-bp repeat motifs in rare alleles were observed to be different from those in common alleles (16) prompted us to hypothesize that this might be the biologic basis for a different behavior of the lymphomas in patients bearing rare alleles.
To our knowledge, neither a comprehensive study on genetic predisposition to NHL in relation to H-RAS 1 VNTR genotypes nor clinical data on the relationship between rare H-RAS 1 VNTR alleles and the prognosis of patients has ever been presented. We were interested, therefore, to determine whether, in a cohort of 125 well-defined cases of NHL with adequate clinical follow-up, we could establish rare H-RAS 1 VNTR alleles as both a new inherited genetic marker of NHL susceptibility and a new independent prognostic factor for this disease.
As inherited genetic factors, H-RAS 1 VNTR alleles can easily be analyzed in DNA from peripheral blood lymphocytes by means of a polymerase chain reaction (PCR)-based assay, thus eliminating the need for tumor tissue samples. Although most previous studies (7, 8, 10, 11) of this locus were based on Southern blot analysis, we employed the PCR assay and long-gel electrophoretic procedures, which are easier to perform and offer much higher resolution. Rare alleles were differentiated from common ones (a1, a2, a3, and a4) by shifts in electrophoretic mobility (Fig.  1) . We obtained peripheral blood samples from 125 patients with NHL and 446 cancer-free control subjects at the Hematology Service of the Hospital Universitari Germans Trias i Pujol of Badalona (Barcelona, Spain). Sequential, unrelated blood donors, as well as other healthy volunteers, were recruited as the controls. Although this was an unmatched case-control study, there were no statistically significant differences between the control subjects and the patients with respect to age, sex, or ethnic background. All study subjects were Spanish Caucasian residents of the surrounding area of Badalona and had no prior history of cancer. Human immunodeficiency virus (HIV)-positive patients were excluded from the study. However, in our sample of 125 patients, little is known either about the role of potential oncogenic viruses other than HIV or about exposure to carcinogens such as 1,3-butadiene, which is used in synthetic rubbers and which has been detected in industrial exhaust and cigarette smoke.
Despite current classification of NHL according to the Revised EuropeanAmerican Lymphoma system (20) , the fact that ours was a retrospective study led us to use the Working Formulation (21), since it allowed us to subgroup the whole series of patients into low-, intermediate-, and high-grade NHL, thus facilitating the management of clinicopathologic data. Disease stage was determined according to the Ann Arbor classification system (22) . Patients with any pathologic subtype of NHL and any clinical stage entered the study; only patients with chronic lymphocytic leukemia were excluded. Median follow-up from the time of diagnosis for the entire series of patients is 31 months (range, 1-216 months).
Patients with intermediate-and highgrade NHL (n ‫ס‬ 95) were treated with potentially curative combination chemotherapies, most of which contained doxorubicin. Seventy-two patients received cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), eight received methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (MACOP-B), and 15 received other therapies. Among the patients with low-grade NHL (n ‫ס‬ 30), 16 were treated with chlorambucil and prednisone, and 14 received cyclophosphamide, mitoxantrone, vincristine, and prednisone (CNOP). All regimens were given at standard-dose intensities (4) .
Associations between the presence of rare alleles and clinical parameters were examined by use of chi-squared and Fisher's exact tests. The probability of overall survival was computed according to the Kaplan-Meier method. Statistical comparisons between survival curves were based on the logrank test. Relationships between prognostic factors were determined by use of the Cox's proportional hazard ratio model for covariate analysis of censored data. Odds ratios (ORs; estimates of relative risk) and 95% confidence intervals (CIs) were calculated according to the Cornfield method. Statistical significance was defined as two-sided P<.05.
We analyzed 892 H-RAS 1 VNTR alleles from the 446 control subjects and 250 alleles from the 125 patients with NHL. While in the former group only 13% (115 of 892) of the alleles were rare, 23% (58 of 250) of the alleles in the NHL group were rare. The relative risk of NHL associated with the presence of rare alleles was 2.04 (95% CI ‫ס‬ 1.4-2.9) (P ‫ס‬ .0001). We also found that the number of individuals in the NHL group harboring at least one rare allele (47 [38%] of 125) was significantly higher than in the control group (94 [27%] of 352) (OR ‫ס‬ 2.2; 95% CI ‫ס‬ 1.4-3.6) (P ‫ס‬ .0001). Table 1 shows characteristics of the patients grouped according to the number of rare alleles (0, 1, or 2) in their H-RAS 1 VNTR genotype. Patients in the three groups did not differ significantly in any of the main clinicopathologic features (sex, histologic subtype, clinical stage, constitutional symptoms, serum lactate dehydrogenase level, and serum ␤2-microglobulin level). There was also no association between the presence of rare alleles and risk group defined by the International Prognostic Index (IPI) (23) . Although the IPI was originally developed only for intermediate-and high-grade NHL, other studies (24, 25) have shown its value as a prognostic parameter for low-grade NHL. That is why we did not limit its use to patients with intermediate-and highgrade NHL in this study but also applied it to the low-grade NHL group.
To assess the prognostic value of rare alleles, we divided the whole series of patients into groups having either lowgrade NHL or intermediate-and highgrade NHL, and, in turn, we divided each of these two groups into rare allelenegative and allele-positive subgroups. We found that the patients with lowgrade NHL who had rare alleles in their genotype had a worse prognosis than patients with low-grade NHL and no rare alleles (P<.001, logrank test). The 5-year actuarial survival rate for the patients with low-grade NHL and no rare alleles was 96.5% (95% CI ‫ס‬ 93-100); the survival rate for patients with lowgrade NHL and one rare allele was 83% (95% CI ‫ס‬ 62-99); the rate for patients with low-grade NHL and two rare al- New England Biolabs, Inc., Beverly, MA), and 150 ng of genomic DNA. PCR was run in a final volume of 50 L on a Perkin-Elmer Cetus 9600 Gene Amp PCR thermocycler (Perkin-Elmer Cetus, Norwalk, CT) using the following temperature program: 94°C for 5 minutes followed by 30 cycles each of 1 minute at 94°C, 3 minutes at 68°C, and 3 minutes at 72°C. A final extension step at 72°C for 4 minutes was added to terminate the amplification. The sequences of the primers were as follows: sense, 5Ј-GCT CCT GGC CTC GGG AAG TCT AT-3Ј; antisense, 5Ј-AGA GCT AGC AGG GCA TGC CGC T-3Ј. Amplified products were separated by electrophoresis in 1× Trisacetate-EDTA buffer (Life Technologies, Inc., Gaithersburg, MD) through 1.2% agarose gels (40 cm in length) for 15-18 hours at a constant voltage of 2 V/cm. Molecular weight markers that differed by increments of 100 and 500 bp (L) were loaded together with PCR products in every 6th to 7th well. Gels were stained with ethidium bromide and photographed under UV light using a Polaroid DS34 camera system and type 669 film (Polaroid, Hertfordshire, U.K.). leles was 54.5% (95% CI ‫ס‬ 10-99) (P ‫ס‬ .0009, logrank test). Similarly, in the group of patients with intermediate/ high-grade NHL, those with no rare alleles had a better prognosis (5-year actuarial survival rate of 92% [95% CI ‫ס‬ 84-100]) than those with one or two rare alleles (5-year actuarial survival rate of 78% [95% CI ‫ס‬ 76-80]), but the survival difference was not statistically significant (P ‫ס‬ .07). However, the high overall survival in the subgroup of patients with intermediate/high grade NHL and no rare alleles could be the result of bias due to the inclusion of cases with longer survival. When considering all 125 patients in the series, those with no rare alleles had a higher survival rate than those with at least one rare allele (P ‫ס‬ .005, logrank test). Moreover, when taking into account not only the presence or absence but also the number of rare alleles, we found that patients with two common alleles had a higher estimated survival probability than those with one common/one rare allele, who had, in turn, a higher survival rate than patients bearing two rare alleles (P ‫ס‬ .01, logrank test).
In our univariate analysis, we also identified, apart from the rare alleles, other classical adverse prognostic factors for survival, such as high IPI risk group (P ‫ס‬ .009), elevated serum ␤2-microglobulin level in intermediate/ high-grade NHL (P ‫ס‬ .003), and elevated serum lactate dehydrogenase level in intermediate/high-grade NHL (P ‫ס‬ .04). We used the Cox's proportional hazards regression model to assess survival, adjusting for all wellestablished prognostic factors for NHL. In addition to the number of rare alleles in the H-RAS 1 VNTR genotype and the IPI risk group, all other clinicopathologic parameters assessed in this study, such as sex, serum ␤2-microglobulin level, and histologic subtype of NHL, were included in the multivariate analysis but did not emerge as independent prognostic factors. The only independent prognostic factors were the number of rare alleles and the IPI risk group, with the relative risks of death being 1.9 (95% CI ‫ס‬ 1.1-3.4) (P ‫ס‬ .03) for patients with one or two rare alleles and 1.6 (95% CI ‫ס‬ 1.1-2.4) (P ‫ס‬ .02) for patients in the IPI group at high risk.
To date, only two studies (7, 12) on inherited genetic predisposition to NHL based on H-RAS 1 VNTR genotype have been published, both with a low number of patients (five and 50, respectively). In the former study, no association was established between H-RAS 1 VNTR rare alleles and NHL risk; in the latter, an association was established, but it was not statistically significant. On the basis of these studies, we attempted to verify whether, by analyzing a greater number of patients and control subjects, this genetic locus could be shown to be a determinant of increased genetic susceptibility to NHL. Our results show that the presence of rare alleles at H-RAS 1 VNTR indicates both an increased inherited genetic susceptibility to NHL and also an adverse prog- nosis, especially in low-grade NHL. Moreover, this study gives the first evidence for the existence of an inherited genetic alteration that may place individuals at increased risk of NHL, apart from those alterations present in rare congenital diseases (ataxiatelangiectasia, with DNA-processing and repair defects, and FAS gene mutations in Canale-Smith syndrome) (26) that are associated with an increased incidence of NHL. Prognostic factors in NHL have been limited to those related to the tumor itself, such as histology, clinical stage, tumor size and burden, serum lactate dehydrogenase and ␤2-microglobulin levels, and karyotype or molecular abnormalities. Here we present, for the first time, a potential independent prognostic factor for NHL that is not tumor dependent but is determined in the patient's genome before disease onset, i.e., rare alleles of the H-RAS 1 VNTR. Furthermore, the combination of rare alleles and a high IPI risk group is associated with an unfavorable clinical course in patients with NHL.
We conclude that PCR analysis of H-RAS 1 VNTR alleles in samples of peripheral blood obtained at any time during the natural history of NHL is a potentially useful approach for determining genetic predisposition to this disease and for identifying a subset of patients with NHL that might be at high risk of death, especially in low-grade disease. Further studies on H-RAS 1 proto-oncogene expression related to the H-RAS 1 VNTR genotype are clearly warranted to validate our results. Such studies would shed light on the complexity of the rare allele sequences and their expression as well as on their potential influence on both NHL risk and prognosis.
